comparemela.com

Latest Breaking News On - Revance therapeutics inc - Page 1 : comparemela.com

Rhenman & Partners Asset Management AB Has $4.18 Million Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]

United-states
Dustins-sjuts
Piper-sandler
Tobin-schilke
Quest-partners
Capstone-investment-advisors
Nasdaq
Revance-therapeutics-inc
Needham-company
Exchange-commission
Goldman-sachs-group
Asset-management-inc

Rhenman & Partners Asset Management AB Has $4.18 Million Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]

United-states
Tobin-schilke
Piper-sandler
Dustins-sjuts
Asset-management-inc
Goldman-sachs-group
Needham-company
Exchange-commission
Revance-therapeutics-inc
Nasdaq
Capstone-investment-advisors
Quest-partners

Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average […]

United-states
Piper-sandler
Tobin-schilke
Nasdaq
Needham-company
Principal-financial-group-inc
Goldman-sachs-group
Barclays
Securities-exchange-commission
Revance-therapeutics-inc
Vanguard-group-inc
Revance-therapeutics-company-profile

Analysts Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Price Target at $11.50

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The […]

United-states
Los-angeles
California
Zurcher-kantonalbank-zurich-cantonalbank
Tobin-schilke
Piper-sandler
Securities-exchange-commission
Nasdaq
Revance-therapeutics-company-profile
Goldman-sachs-group
Barclays
Los-angeles-capital-management

Revance Therapeutics (NASDAQ:RVNC) Price Target Lowered to $8.00 at The Goldman Sachs Group

Revance Therapeutics (NASDAQ:RVNC) Price Target Lowered to $8.00 at The Goldman Sachs Group
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Piper-sandler
Dustins-sjuts
Tobin-schilke
Revance-therapeutics-company-profile
Barclays
Asset-management-inc
Needham-company
Securities-exchange-commission
Goldman-sachs-group
Invesco-ltd
Revance-therapeutics-inc

vimarsana © 2020. All Rights Reserved.